Overview

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells. It is not yet known if chemotherapy is more effective with or without dexrazoxane for Hodgkin's disease. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy, with or without dexrazoxane, followed by radiation therapy in treating young patients with newly diagnosed stage I, stage II, or stage III Hodgkin's disease.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Children's Oncology Group
Collaborators:
Children's Cancer Group
National Cancer Institute (NCI)
Treatments:
Bleomycin
Cobalt
Dexrazoxane
Doxorubicin
Etoposide
Etoposide phosphate
Lenograstim
Liposomal doxorubicin
Razoxane
Vincristine
Criteria
DISEASE CHARACTERISTICS: Histologically proven Hodgkin's disease No more than 5 weeks since
diagnostic biopsy No B symptoms Clinical/pathologic stages (all histologies) as follows:
Stage IA/IIA with mediastinal mass less than one third of chest diameter Stage IIIA limited
to spleen or splenic, celiac, or portal nodes and lesions no larger than 6 cm Surgical
staging required if: Clinical and imaging findings equivocal Tanner stage IV/V for whom
radiotherapy is planned Concurrent registration on protocols POG-8828 (late effects study)
and POG- 8829 (epidemiology study) required

PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Hematopoietic:
No hematopoietic disease Hepatic: No liver disease Renal: No renal disease Other: No severe
organ or system damage or failure No pregnant or nursing women

PRIOR CONCURRENT THERAPY: No prior therapy